Decreased copy number aberrations in genomes of HER2+ metastatic breast cancer (MBC) patients (pts) with extraordinary durable complete responses (dCR) to trastuzumab (T).
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 610-610
10.1200/jco.2016.34.15_suppl.610